



## **Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference**

January 12, 2026

TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE: PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of [www.prestigeconsumerhealthcare.com](http://www.prestigeconsumerhealthcare.com). To participate in the conference call via phone, participants may register for the call [here](#) to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company's Investor Relations page.

### **ICR Conference**

Separately, the company will also participate in a fireside chat at the 28<sup>th</sup> Annual ICR Conference on Tuesday, January 13, 2026 at 9:30 a.m. ET. Interested parties may access a live audio webcast of this event from the Investor Relations page of [www.prestigeconsumerhealthcare.com](http://www.prestigeconsumerhealthcare.com). A replay of the webcast will be available later that same day.

### **About Prestige Consumer Healthcare Inc.**

Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at [www.prestigeconsumerhealthcare.com](http://www.prestigeconsumerhealthcare.com).

Source: Prestige Consumer Healthcare Inc.

### **Investor Relations Contact**

Phil Terpolilli, CFA, 914-524-6819  
[irinquiries@prestigebrands.com](mailto:irinquiries@prestigebrands.com)



Source: Prestige Consumer Healthcare Inc.